Movement Alert｜LEADS BIOLABS-B Rises 6.18% in Regular Trading, Positive Phase II Data for Welixin Presented at WCLC Boosts Market Confidence

Market Focus

Yesterday

On September 15, LEADS BIOLABS-B rose 6.18% in regular trading, trading at 63.65 HKD/share, with turnover of approximately 29.81 million HKD.

On the news front, the company announced on September 14 that updated Phase II clinical data for its core product Welixin (opatuzumab, a PD-L1/4-1BB bispecific antibody) combined with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) was presented as an oral report at the WCLC 2026 World Conference on Lung Cancer. In the non-squamous NSCLC PD-L1-positive subgroup, the objective response rate reached 81.8%, the disease control rate reached 100.0%, and the 6-month progression-free survival rate was 90.0%. The overall safety profile was favorable, comparable to PD-L1 monoclonal antibody combined with chemotherapy, with no new safety signals observed. The study enrolled 63 previously untreated NSCLC patients, with over 90% being Stage IV. The company is actively advancing Phase III clinical study planning for Welixin in first-line NSCLC. Notably, CLSA previously raised its target price for the company to 116.9 HKD.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/1176880659"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176880659\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176880659?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176880659","market":"us","top_or_hot":-1,"title":"Movement Alert｜LEADS BIOLABS-B Rises 6.18% in Regular Trading, Positive Phase II Data for Welixin Presented at WCLC Boosts Market Confidence","media":"Market Focus","content":"<p><p>On September 15, LEADS BIOLABS-B rose 6.18% in regular trading, trading at 63.65 HKD/share, with turnover of approximately 29.81 million HKD.</p><p>On the news front, the company announced on September 14 that updated Phase II clinical data for its core product Welixin (opatuzumab, a PD-L1/4-1BB bispecific antibody) combined with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) was presented as an oral report at the WCLC 2026 World Conference on Lung Cancer. In the non-squamous NSCLC PD-L1-positive subgroup, the objective response rate reached 81.8%, the disease control rate reached 100.0%, and the 6-month progression-free survival rate was 90.0%. The overall safety profile was favorable, comparable to PD-L1 monoclonal antibody combined with chemotherapy, with no new safety signals observed. The study enrolled 63 previously untreated NSCLC patients, with over 90% being Stage IV. The company is actively advancing Phase III clinical study planning for Welixin in first-line NSCLC. Notably, CLSA previously raised its target price for the company to 116.9 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜LEADS BIOLABS-B Rises 6.18% in Regular Trading, Positive Phase II Data for Welixin Presented at WCLC Boosts Market Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜LEADS BIOLABS-B Rises 6.18% in Regular Trading, Positive Phase II Data for Welixin Presented at WCLC Boosts Market Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-15 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 15, LEADS BIOLABS-B rose 6.18% in regular trading, trading at 63.65 HKD/share, with turnover of approximately 29.81 million HKD.</p><p>On the news front, the company announced on September 14 that updated Phase II clinical data for its core product Welixin (opatuzumab, a PD-L1/4-1BB bispecific antibody) combined with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) was presented as an oral report at the WCLC 2026 World Conference on Lung Cancer. In the non-squamous NSCLC PD-L1-positive subgroup, the objective response rate reached 81.8%, the disease control rate reached 100.0%, and the 6-month progression-free survival rate was 90.0%. The overall safety profile was favorable, comparable to PD-L1 monoclonal antibody combined with chemotherapy, with no new safety signals observed. The study enrolled 63 previously untreated NSCLC patients, with over 90% being Stage IV. The company is actively advancing Phase III clinical study planning for Welixin in first-line NSCLC. Notably, CLSA previously raised its target price for the company to 116.9 HKD.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1176880659","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176880659","pubTimestamp":1789435919,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 15, LEADS BIOLABS-B rose 6.18% in regular trading, trading at 63.65 HKD/share, with turnover of approximately 29.81 million HKD.On the news front, the company announced on September 14...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"走势警报|LEADS BIOLABS-B 常规交易上涨 6.18%，WCLC 上公布的 Welixin II 期积极数据提振市场信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"On September 15, LEADS BIOLABS-B rose 6.18% in regular trading, trading at 63.65 HKD/share, with turnover of approximately 29.81 million HKD.On the news front, the company announced on September 14 that updated Phase II clinical data for its core product Welixin (opatuzumab, a PD-L1/4-1BB bispecific antibody) combined with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) was presented as an oral report at the WCLC 2026 World Conference on Lung Cancer. In the non-squamous NSCLC PD-L1-positive subgroup, the objective response rate reached 81.8%, the disease control rate reached 100.0%, and the 6-month progression-free survival rate was 90.0%. The overall safety profile was favorable, comparable to PD-L1 monoclonal antibody combined with chemotherapy, with no new safety signals observed. The study enrolled 63 previously untreated NSCLC patients, with over 90% being Stage IV. The company is actively advancing Phase III clinical study planning for Welixin in first-line NSCLC. Notably, CLSA previously raised its target price for the company to 116.9 HKD.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}